Irinotecan treatment in cancer patients with UGT1A1 polymorphisms

scientific article (publication date: May 2003)

Irinotecan treatment in cancer patients with UGT1A1 polymorphisms is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P3181OpenCitations bibliographic resource ID4575194
P698PubMed publication ID12800608

P50authorMark J RatainQ87725760
P2093author name stringFederico Innocenti
P433issue5 Suppl 5
P407language of work or nameEnglishQ1860
P921main subjectirinotecanQ412197
P304page(s)52-5
P577publication date2003-05-01
P1433published inOncologyQ1998293
P1476titleIrinotecan treatment in cancer patients with UGT1A1 polymorphisms
P478volume17

Reverse relations

cites work (P2860)
Q37345974Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
Q26741009Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives
Q43284467Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
Q38260248Gene replacement therapy for genetic hepatocellular jaundice
Q28295988Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome)
Q36775605Impact of pharmacogenomics on clinical practice in oncology
Q28287024Irinotecan pharmacogenomics
Q39354491Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition.
Q36190895Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies

Search more.